Rapport Therapeutics Inc
NASDAQ:RAPP

Watchlist Manager
Rapport Therapeutics Inc Logo
Rapport Therapeutics Inc
NASDAQ:RAPP
Watchlist
Price: 11.73 USD -5.25%
Market Cap: 428.1m USD
Section:
Profitability Summary
Profitability Summary
Past Growth
Margins
Return on Capital
Free Cash Flow
See Also

Profitability Summary

Rapport Therapeutics Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less
0
Revenue
+0%
Mar 31, 2025 0
Dec 31, 2024 0
Sep 30, 2024 0
Jun 30, 2024 0
0
Operating Income
+0%
Mar 31, 2025 -94m
Dec 31, 2024 -83m
Sep 30, 2024 -96.2m
Jun 30, 2024 -74.2m
0
Net Income
+0%
Mar 31, 2025 -80m
Dec 31, 2024 -78m
Sep 30, 2024 -93.8m
Jun 30, 2024 -75.8m

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Rapport Therapeutics Inc

Revenue
0 USD
Operating Expenses
-94m USD
Operating Income
-94m USD
Other Expenses
14m USD
Net Income
-80m USD

Margins Comparison
Rapport Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin 		Net
Margin
US
Rapport Therapeutics Inc
NASDAQ:RAPP
422.3m USD N/A N/A
US
Eli Lilly and Co
NYSE:LLY
754.1B USD
40%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
367.2B USD
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
45%
35%
CH
Roche Holding AG
SIX:ROG
208.9B CHF
33%
14%
CH
Novartis AG
SIX:NOVN
188.5B CHF
33%
24%
UK
AstraZeneca PLC
LSE:AZN
157.3B GBP
24%
14%
US
Merck & Co Inc
NYSE:MRK
199.7B USD
34%
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
11%
-126%
US
Pfizer Inc
NYSE:PFE
137.9B USD
27%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Rapport Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Rapport Therapeutics Inc
NASDAQ:RAPP
422.3m USD
-33%
-32%
-38%
-60%
US
Eli Lilly and Co
NYSE:LLY
754.1B USD
78%
14%
38%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
367.2B USD
30%
12%
18%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
88%
27%
70%
30%
CH
Roche Holding AG
SIX:ROG
208.9B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
188.5B CHF
33%
13%
26%
18%
UK
AstraZeneca PLC
LSE:AZN
157.3B GBP
20%
7%
18%
14%
US
Merck & Co Inc
NYSE:MRK
199.7B USD
39%
16%
25%
19%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
137.9B USD
9%
4%
10%
9%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less

See Also

Summary
RAPP intrinsic value, competitors valuation, and company profile.
DCF Valuation
RAPP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RAPP stock valuation using valuation multiples.
Wall Street Estimates
RAPP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RAPP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 264,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.